Meta-analysis results for all treatments

Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method

Treament Trials
Summary Endpoints
     
Demonstrated or suggested benefit Inconclusive results Uncertain results Safety results
chloroquine and derivatives4noneinconclusive results for: death D28; deaths; deaths (time to event analysis only); clinical deterioration; clinical improvement (time to event analysis only); hospital discharge; ICU admission; off oxygenation

suggested 86 % decrease in mechanical ventilation but the degree if certainty is unassessable

-
ivermectin3noneinconclusive results for: deaths; deaths (time to event analysis only); clinical improvement; clinical improvement (7-day); viral clearance ; ICU admission

suggested 86 % decrease in mechanical ventilation but the degree if certainty is unassessable

-
lopinavir/ritonavir2noneinconclusive results for: deaths; deaths (time to event analysis only); clinical improvement; clinical improvement (14-day); clinical improvement (28-day); clinical improvement (7-day); clinical improvement (time to event analysis only); death or ventilation; hospital discharge; serious adverse events--
azithromycin1noneinconclusive results for: death D28; deaths; deaths (time to event analysis only); clinical improvement; clinical improvement (14-day); clinical improvement (28-day); clinical improvement (7-day); related SAE (TRSAE); serious adverse events; long QT; renal impairment--
favipiravir 1noneinconclusive results for: deaths; hospital discharge--
Lopinavir/ritonavir plus hydroxychloroquine1noneinconclusive results for: clinical improvement; clinical improvement (14-day); hospital discharge; serious adverse events

suggested 42 % decrease in deaths but the degree if certainty is unassessable

suggested 42 % decrease in deaths (time to event analysis only) but the degree if certainty is unassessable

-
remdesivir1noneinconclusive results for: deaths; clinical deterioration; clinical improvement; clinical improvement (14-day); clinical improvement (28-day); clinical improvement (7-day); clinical improvement (time to event analysis only); AE leading to drug discontinuation; serious adverse events; deep vein thrombosis; elevated liver enzymes; hyperbilirubinemia; pulmonary embolism; renal impairment--
sofosbuvir and daclatasvir1noneinconclusive results for: adverse events

suggested 88 % decrease in death D28 but the degree if certainty is unassessable

suggested 88 % decrease in deaths but the degree if certainty is unassessable

suggested 78 % decrease in ICU admission but the degree if certainty is unassessable

suggested 8.3-fold increase in recovery but the degree if certainty is unassessable

-
Amantadine0- - - -
ASC09/ritonavir0- - - -
azvudine0- - - -
baloxavir marboxil0- - - -
bromhexine0- - - -
carrimycin0- - - -
danoprevir / ritonavir0- - - -
darunavir cobicistat0- - - -
doxycycline0- - - -
Emtricitabine/tenofovir plus colchicine plus rosuvastatin0- - - -
Ensitrelvir (XOCOVA)0- - - -
favipiravir plus interferon0- - - -
fluvoxamine0- - - -
hydroxychloroquine plus macrolides0- - - -
Interferon plus lopinavir/ritonavir0- - - -
leronlimab0- - - -
lopinavir / ritonavir plus ribavirin0- - - -
lopinavir/ritonavir plus chloroquine0- - - -
lopinavir/ritonavir plus interferon ß-1a0- - - -
lopinavir/ritonavir, ribavirin and interferon beta-1b0- - - -
molnupiravir0- - - -
niclosamide0- - - -
nirmatrelvir / ritonavir (Paxlovid)0- - - -
nitazoxanide0- - - -
opaganib0- - - -
oseltamivir0- - - -
oseltamivir plus chloroquin0- - - -
ribavirin0- - - -
ritonavir0- - - -
sofosbuvir0- - - -
sofosbuvir and ledipasvir0- - - -
tenofovir/emtricitabine0- - - -
tenofovir/emtricitabine plus hydroxychloroquine0- - - -
tranexamic acid0- - - -
tranilast0- - - -
triazavirin0- - - -
umifenovir (arbidol)0- - - -
zinc0- - - -

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons